Advanced Biomed receives Nasdaq bid price deficiency notice; has 180 days to regain compliance

Advanced Biomed Inc.

Nasdaq notified ADVB on July 18, 2025, of bid price below $1.00 for 32 consecutive business days.
Company has until Jan 14, 2026 to regain compliance; must close at $1.00+ for 10 consecutive days.
If not cured, ADVB may get an extra 180 days if it meets other Nasdaq initial listing standards.
Company may consider a reverse stock split or other options to remedy the deficiency.
Common stock continues trading under symbol ADVB on Nasdaq Capital Market with no immediate impact.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.